Canada - English - Health Canada

pfizer canada ulc - pamidronate disodium - solution - 9mg - pamidronate disodium 9mg - bone resorption inhibitors

Canada - English - Health Canada

fresenius kabi canada ltd - pamidronate disodium - solution - 3mg - pamidronate disodium 3mg - bone resorption inhibitors

Canada - English - Health Canada

fresenius kabi canada ltd - pamidronate disodium - solution - 6mg - pamidronate disodium 6mg - bone resorption inhibitors

Canada - English - Health Canada

fresenius kabi canada ltd - pamidronate disodium - solution - 9mg - pamidronate disodium 9mg - bone resorption inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pamidronate disodium, quantity: 9 mg - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections; phosphoric acid; mannitol - treatment of conditions associated with increased osteoclast activity predominantly lytic bone metastases from breast cancer and advanced multiple myeloma. acute management of tumour-induced hypercalcaemia (hypercalcaemia of malignancy). treatment of symptomatic paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pamidronate disodium, quantity: 6 mg - injection, concentrated - excipient ingredients: mannitol; water for injections; sodium hydroxide; phosphoric acid - treatment of conditions associated with increased osteoclast activity predominantly lytic bone metastases from breast cancer and advanced multiple myeloma. acute management of tumour-induced hypercalcaemia (hypercalcaemia of malignancy). treatment of symptomatic paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pamidronate disodium, quantity: 3 mg - injection, concentrated - excipient ingredients: mannitol; phosphoric acid; water for injections; sodium hydroxide - treatment of conditions associated with increased osteoclast activity predominantly lytic bone metastases from breast cancer and advanced multiple myeloma. acute management of tumour-induced hypercalcaemia (hypercalcaemia of malignancy). treatment of symptomatic paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - pamidronate disodium, quantity: 3 mg - injection, concentrated - excipient ingredients: phosphoric acid; mannitol; sodium hydroxide; water for injections - treatment of conditions associated with increased osteoclast activity: predominantly lytic bone metastases from breast cancer and advanced multiple myeloma. acute management of tumour-induced hypercalcaemia (hypercalcaemia of malignancy). treatment of symptomatic paget's disease of bone.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - disodium pamidronate -

Malta - English - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - pamidronate disodium - concentrate for solution for infusion - pamidronate disodium 3 mg/ml - drugs for treatment of bone diseases